BNB Plus Corp. announced on October 2, 2026, that it is transitioning from a digital asset treasury company focused on the BNB Chain ecosystem to an operating company deploying infrastructure for blockchain and agentic AI.
The company, formerly known as Applied DNA Sciences, Inc., stated it will redirect its strategic focus from holding digital assets to building the infrastructure, software, and services required for financial institutions and enterprises to adopt emerging open network technologies. BNB Plus Corp. believes value creation will shift toward operating the complex layers necessary to put these technologies to work at institutional scale, providing security, resilience, risk management, and regulatory compliance.
To facilitate this shift, the company is evaluating an expansion of its relationship with GlobalStake Infrastructure LLC, which has been leading its strategic review. GlobalStake holds SOC 2 Type II certification and operates as a Web3 infrastructure firm. The company manages validator nodes and generates yield while offering strategic advisory support to protocol foundations, institutional investors, custodians, and exchanges. It maintains sovereign bare-metal infrastructure across major blockchain networks and serves as a staking yield partner for leading custodians, exchanges, and wallet providers.
Richard Shorten, Chairman of BNB Plus Corp. and Founder of GlobalStake, said that Web3 introduced a way of thinking about open networks that becomes more valuable as AI matures. He stated that decentralization, data sovereignty, and bespoke infrastructure capable of enterprise-grade risk management are core disciplines for the next generation of open financial systems. Shorten added that the company intends to pioneer the transformation of these technologies into institutional-grade financial infrastructure capable of supporting real-world financial and commercial activity.
BNB Plus Corp. also plans to evaluate options to strengthen the strategic positioning of its subsidiary, LineaRx, Inc., within the genetic medicines market. The objective is to realize the value of LineaRx for stockholders. LineaRx’s enzymatic DNA manufacturing platform produces high-quality DNA used in the manufacture of mRNA and other genetic medicines.
Clay Shorrock, Chief Executive Officer of BNB Plus Corp. and President of LineaRx, said the industry’s recent Phase 3 success of a personalized mRNA cancer therapy indicates that individualized treatments can deliver meaningful clinical benefit. He stated that the growth of genetic medicines will require a fast, reliable source of high-quality DNA, and that LineaRx is built to supply it.
The company expects to remain an active participant in the BNB Chain ecosystem while focusing on providing integration capabilities and deployment resources. The press release includes forward-looking statements regarding the strategic transition, plans for infrastructure assembly, and the anticipated benefits of the relationship with GlobalStake. These statements are subject to risks and uncertainties, including the company’s ability to execute its operating strategy, volatility in digital asset prices, changes in the regulatory environment, and unknown future demand for genetic medicines.